US indexes advance with investors continuing to evaluate the risks posed by the Omicron variant
12.05pm:
Major US indexes advanced midday after three consecutive sessions of declines with investors continuing to evaluate the risks posed by the Omicron variant of coronavirus.
The Dow Jones Industrial Average added 153 points, or 0.4%, while the tech-heavy Nasdaq Composite was ahead 139 points, or 0.9%. Meanwhile, the S&P 500 rose 34 points, or 0.7% to 4,683.
“We remain caught within a period of uncertainty as markets attempt to gauge exactly how disruptive this Omicron wave is going to be for businesses,” said Joshua Mahony, Senior Market Analyst at IG, a global online trading platform.
“The upgraded third quarter GDP reading out of the US helped highlight how the economy continued to strengthen over the course of September, putting the 2021 figure on track for the best rate of growth since 1984. Nonetheless, we are widely expecting to see economic activity drop-off in the coming weeks, with Christmas sales taking a hit as cases and hospitalisations rise.”
10am: Proactive North America headlines:
Tesla boss Elon Musk sells “enough stock” to reach 10% goal
Harbor Custom Development closes $4.8M sale of 24 developed lots in Washington to MainVue Homes
Potent Ventures announces plans to change its name to The Gummy Project
Cypress Development pleased with pilot plant’s performance in Nevada as it extends lease of facility to 2025
CLS Holdings USA (CSE:CLSH, OTCQB:CLSH) says its City Trees brand wins first place in two categories at High Times Cannabis Cup
Global Energy Metals well positioned for success as world turns to greener future, says CEO Smith
The Valens Company (TSX:VLNS, OTCQX:VLNCF) partners with Montreal Cannabis Médical for extraction and manufacturing of pre-rolls and vapes
Mednow sees fiscal 1Q revenue growth speed up as it builds digital pharmacies and interdisciplinary model of care across Canada
Mydecine to work with Maya to develop a novel digital therapeutics platform for more personalized patient care
Victory Resources identifies two ‘significant’ anomalies from IP survey at Mal-Wen; terminates agreement with Silver Range Resources (AIM:RRL, ASX:RRS) on Loner
American Manganese says 2021 has laid a “strong foundation” for growth next year
9.50am: Wall Street makes muted start
US stocks made a muted to flat start on Wednesday as traders continued to fret about the Omicron variant ahead of the holiday weekend.
In New York, the Dow Jones Industrial Average added around nine points at 35,502.
The S&P 500 was near flat at 4,648, while the Nasdaq Composite Index lost around 23 points to stand at 15,317.
“Trading volumes will continue to fall heading into the holiday weekend, but risk appetite will struggle to deliver a significant stock market rally as the Omicron variant still poses a major risk for many healthcare systems,” said Edward Moya, senior market analyst at Oanda, who noted the rush was now on to secure treatments.
“The Biden administration is expected to acquire 4 million courses of COVID-19 treatments by the end of January, while the UK secured 1.75 million courses of Merck’s COVID pill and 2.5 million courses of Pfizer’s COVID treatment,” he said.
“In the US, a return to lockdowns seen earlier in the pandemic are unlikely, but the US consumer will be weaker as many Americans won’t have the same benefits if their jobs have tentative closures,” he added.
In company news, Tesla shares accelerated over 4% higher after Elon Musk revealed he had reached his goal of selling 10% of his shares for tax reasons.
6.30am: US shares set to ease back
US stocks look set to ease back on Wednesday reversing some of the previous session’s gains which saw it snap a three-day losing streak as hopes for a Santa rally are balanced by fears over the Omicron coronavirus (COVID-19) variant.
Futures for the Dow Jones Industrial Average were 0.1% lower, those for the S&P 500 index ticked down 0.2%, and contracts for the Nasdaq-100 shed 0.3%.
Stocks have been see-sawing in the run-up to Christmas as investors seek to determine how severe the economic impact of the rapid spread of the Omicron variant will be.
Investors are also preparing for the Federal Reserve to raise interest rates in 2022 and squaring positions before the year-end.
On the data front, The Conference Board’s latest consumer confidence index, due at 10.00am ET, is forecast to tick higher, after inflation and the pandemic knocked sentiment in November.
Real estate market data, due at the same time, are expected to show sales of existing homes rose for a third consecutive month in November.
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/969979/us-indexes-advance-with-investors-continuing-to-evaluate-the-risks-posed-by-the-omicron-variant-969979.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
